Board of Directors

Fenel Eloi

Fenel Eloi is a highly seasoned life science executive experienced in leading the transformation of small and mid-size companies to large operating global organizations.  During his professional career, Fenel has scaled up operations, expanded businesses both organically and through strategic partnerships and completed a number of public and private financing transactions.  He was most recently the Chief Financial Officer and then Chief Operating Officer of Cell Signaling Technology, Inc., a privately held life sciences company, where he oversaw significant growth of the business over a period of 12 years and provided leadership in the transformation of the company to a global operation.  Prior to that, he was the Chief Operating Officer and Chief Financial Officer of Interleukin Genetics, Inc., a formerly NASDAQ-listed diagnostic company, for 5 years.  Prior to Interleukin, he was Chief Financial Officer at LifeCell Corp and Genome Therapeutics Corp, both formerly NASDAQ-listed companies, for a combined period of twelve years.    

Fenel serves on the board of directors and as a member of the Audit Committee of Standard BioTools Inc. He serves on the board of directors and as Chair of the Audit Committee of each of MitoTherapeutix and Ultivue, Inc. Fenel also serves on the board of directors of each of Vaxess Technologies Inc. and VIC Technology Venture Development. He is a Managing Partner at P&M Capital Partners.  He previously served on the board of Cell Signaling Technology, Inc. and BioHelix Corporation.

Fenel has an MBA from Anna Maria College and a BA in Business and Finance from Lee University.